Trial
NCT05111561
Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast Cancer
Phase ISUSPENDEDOTHER/UNKNOWNConfidence: LOW
Sponsor
National Cancer Institute (NCI)
Collaborators
—
Condition
Advanced Malignant Solid Neoplasm
Intervention
BET Bromodomain Inhibitor ZEN-3694
Why stopped
Other - Amendment needed to add new dose level.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-06-17